FOLD,VRTX Stock Price and Quote

NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Dollar change +0.23
Percentage change 3.85	%

Peers: VRTX SRPT BMRN REGN CRSP EDIT PFE QURE AGIO BLUE

| Held by: VTI VB IWM VBK VXF XBI IWO VTWO IBB SCHA

Index	RUT	P/E	-	EPS (ttm)	-0.09	Insider Own	3.38%	Shs Outstand	307.92M	Perf Week	-4.90%
Market Cap	1.91B	Forward P/E	24.04	EPS next Y	0.26	Insider Trans	-0.08%	Shs Float	297.53M	Perf Month	-4.61%
Income	-29.37M	PEG	-	EPS next Q	-0.11	Inst Own	96.08%	Short Float	6.18%	Perf Quarter	-35.58%
Sales	543.14M	P/S	3.52	EPS this Y	51.94%	Inst Trans	-1.90%	Short Ratio	5.02	Perf Half Y	-44.75%
Book/sh	0.63	P/B	9.88	EPS next Y	398.57%	ROA	-3.89%	Short Interest	18.38M	Perf Year	-38.76%
Cash/sh	0.81	P/C	7.63	EPS next 5Y	-	ROE	-18.12%	52W Range	5.82 - 12.65	Perf YTD	-34.08%
Dividend Est.	-	P/FCF	1187.73	EPS past 5Y	34.10%	ROI	-4.67%	52W High	-50.91%	Beta	0.62
Dividend TTM	-	Quick Ratio	2.47	Sales past 5Y	24.32%	Gross Margin	89.08%	52W Low	6.70%	ATR (14)	0.37
Dividend Ex-Date	-	Current Ratio	3.34	EPS Y/Y TTM	80.86%	Oper. Margin	8.80%	RSI (14)	34.67	Volatility	5.89% 4.67%
Employees	499	Debt/Eq	2.29	Sales Y/Y TTM	28.25%	Profit Margin	-5.41%	Recom	1.50	Target Price	15.82
Option/Short	Yes / Yes	LT Debt/Eq	2.25	EPS Q/Q	55.88%	Payout	-	Rel Volume	1.83	Prev Close	5.98
Sales Surprise	-7.82%	EPS Surprise	-29.15%	Sales Q/Q	13.45%	Earnings	May 01 BMO	Avg Volume	3.66M	Price	6.21
SMA20	-8.30%	SMA50	-19.64%	SMA200	-36.07%	Trades		Volume	6,698,106	Change	3.85%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-13-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$17 → $12
Sep-06-24	Initiated	Jefferies	Buy	$18
May-30-24	Initiated	Wells Fargo	Overweight	$18
May-14-24	Upgrade	Guggenheim	Neutral → Buy	$13
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$15 → $20
Sep-09-22	Initiated	Morgan Stanley	Equal-Weight	$14
Apr-13-22	Resumed	Goldman	Neutral	$11
Jan-14-22	Upgrade	SVB Leerink	Mkt Perform → Outperform	$12 → $16
Nov-15-21	Upgrade	Stifel	Hold → Buy	$12 → $16
Sep-30-21	Upgrade	JP Morgan	Neutral → Overweight	$16
Jul-19-21	Resumed	BTIG Research	Buy	$15
May-27-21	Initiated	Needham	Hold
May-21-21	Initiated	UBS	Buy	$16
Apr-14-21	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$17
Mar-02-21	Initiated	Stifel	Hold	$13
Feb-12-21	Downgrade	JP Morgan	Overweight → Neutral	$19
Feb-12-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$30 → $17
Dec-28-20	Resumed	Cantor Fitzgerald	Overweight	$20 → $30
Dec-10-20	Downgrade	Citigroup	Buy → Neutral	$20 → $27
Nov-11-20	Initiated	Berenberg	Hold

Show Previous Ratings

May-07-25 07:00AM	Amicus Therapeutics to Present at the Bank of America 2025 Health Care Conference (GlobeNewswire)
May-02-25 01:18PM	FOLD Q1 Earnings and Sales Miss Estimates, Stock Falls (Zacks)
May-01-25 04:24PM	Amicus Therapeutics, Inc. (FOLD) Q1 2025 Earnings Call Transcript (Seeking Alpha) -13.02%
10:44AM	Dimerix and Amicus to commercialise DMX-200 in US (Pharmaceutical Technology)
09:48AM	Bausch Health Q1 Earnings and Revenues Miss Estimates, Stock Down (Zacks)
08:15AM	Loading…
08:15AM	Amicus Therapeutics (FOLD) Q1 Earnings and Revenues Lag Estimates (Zacks)
07:17AM	Amicus Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates (GlobeNewswire)
Apr-30-25 07:12PM	Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States (GlobeNewswire)
Apr-29-25 10:01AM	Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q1 Earnings Expected to Decline (Zacks)
Apr-24-25 10:01AM	Amicus Therapeutics (FOLD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Apr-23-25 12:57PM	Is Amicus Therapeutics, Inc. (FOLD) Among the Best Guru Stocks to Buy According to Wall Street Analysts? (Insider Monkey)
09:25AM	Amicus Therapeutics to Report Q1 Earnings: What's in the Cards? (Zacks)
Apr-21-25 07:00AM	Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025 (GlobeNewswire)
Apr-17-25 08:21AM	4 Healthcare Stocks to Buy as the Sector Faces Government Heat (Zacks)
08:17AM	Loading…
Apr-15-25 08:17AM	BMY Down on Heart Drug Camzyos Failure in Late-Stage Study (Zacks)
Apr-11-25 01:18PM	Bayer Obtains Full FDA Approval for Oncology Drug Vitrakvi (Zacks)
08:21AM	Is ??Amicus Therapeutics, Inc. (FOLD) the Best Low Priced Growth Stock To Invest In? (Insider Monkey)
Apr-09-25 01:44PM	BMY Gets FDA Nod for Label Expansion of Opdivo plus Yervoy Combo (Zacks)
10:58AM	RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks (Zacks)
Apr-08-25 10:06AM	Is Amicus Therapeutics, Inc. (FOLD) the Best Low Cost Stock to Buy According to Billionaires? (Insider Monkey) -6.01%
Apr-07-25 01:22PM	5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025 (Zacks)
Apr-02-25 01:38PM	GRI Stock Down on Public Offering Despite Encouraging IPF Study Data (Zacks)
Apr-01-25 03:00PM	CHMP Issues Positive Opinion for Label Expansion of BMY's Opdivo (Zacks)
10:50AM	CORT Shares Rise as Relacorilant Combo Meets Ovarian Cancer Study Goal (Zacks)
06:55AM	New Strong Buy Stocks for April 1st (Zacks)
Mar-28-25 12:00PM	abrdn Focused U.S. Small Cap Active ETF Q4 2024 Commentary (Seeking Alpha)
Mar-21-25 11:30AM	Amicus Therapeutics (FOLD) Up 0.1% Since Last Earnings Report: Can It Continue? (Zacks)
10:10AM	Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio (Zacks)
Mar-17-25 03:37PM	Is Amicus Therapeutics Inc. (FOLD) the Best Nasdaq Stock Under $20 to Buy Now? (Insider Monkey)
07:29PM	Loading…
Mar-12-25 07:29PM	Amicus Therapeutics, Inc. (FOLD): Among the Stocks Under $10 With High Upside Potential (Insider Monkey)
Feb-27-25 07:00AM	Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025 (GlobeNewswire)
Feb-23-25 01:30PM	Why Amicus Therapeutics, Inc. (FOLD) is the Most Oversold Pharma Stock to Buy According to Analysts (Insider Monkey)
Feb-20-25 09:30AM	Compared to Estimates, Amicus Therapeutics (FOLD) Q4 Earnings: A Look at Key Metrics (Zacks) -5.13%
02:05AM	Amicus Therapeutics Inc (FOLD) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
02:03AM	Q4 2024 Amicus Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-19-25 08:30AM	Amicus Therapeutics (FOLD) Q4 Earnings and Revenues Miss Estimates (Zacks)
07:00AM	Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates (GlobeNewswire)
Feb-17-25 09:16AM	Insights Into Amicus Therapeutics (FOLD) Q4: Wall Street Projections for Key Metrics (Zacks)
Feb-12-25 10:00AM	Amicus Therapeutics (FOLD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Feb-10-25 07:00AM	Amicus Therapeutics to Announce Full-Year 2024 Financial Results on February 19, 2025 (GlobeNewswire)
Feb-03-25 07:00AM	Amicus Therapeutics Announces Presentations and Posters at the 21st Annual WORLDSymposium 2025 (GlobeNewswire)
Jan-20-25 02:58PM	Is Amicus Therapeutics (FOLD) Among Billionaire Joseph Edelmans Long-Term Stock Picks? (Insider Monkey)
Jan-17-25 11:19AM	Amicus Therapeutics, Inc. (FOLD): The Biotech Stock with Biggest Upside Potential (Insider Monkey)
Jan-12-25 04:00PM	Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook (GlobeNewswire)
09:35AM	Is Amicus Therapeutics (FOLD) the Best Medical Stock to Buy Under $20? (Insider Monkey)
Jan-02-25 07:00AM	Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-13-24 02:10PM	Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday? (Benzinga) -7.78%
09:50AM	Amicus Therapeutics (FOLD) is a Top-Ranked Momentum Stock: Should You Buy? (Zacks)
Dec-06-24 11:31AM	Why Is Amicus Therapeutics (FOLD) Down 11.1% Since Last Earnings Report? (Zacks)
Nov-07-24 09:50AM	Here's Why Amicus Therapeutics (FOLD) is a Strong Momentum Stock (Zacks)
02:09AM	Amicus Therapeutics Inc (FOLD) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
12:26AM	Q3 2024 Amicus Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-06-24 08:30PM	Here's What Key Metrics Tell Us About Amicus Therapeutics (FOLD) Q3 Earnings (Zacks)
08:25AM	Amicus Therapeutics (FOLD) Q3 Earnings and Revenues Beat Estimates (Zacks)
07:22AM	Amicus Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Amicus Therapeutics Announces Third Quarter 2024 Financial Results and Corporate Updates (GlobeNewswire)
Nov-04-24 09:55AM	Wall Street Analysts Predict a 51.09% Upside in Amicus Therapeutics (FOLD): Here's What You Should Know (Zacks)
Nov-01-24 07:00AM	Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024 (GlobeNewswire)
Oct-30-24 10:01AM	Amicus Therapeutics (FOLD) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Oct-28-24 07:00AM	Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024 (GlobeNewswire)
Oct-21-24 09:50AM	Why Amicus Therapeutics (FOLD) is a Top Momentum Stock for the Long-Term (Zacks)
Oct-18-24 12:20PM	Can Amicus Therapeutics (FOLD) Run Higher on Rising Earnings Estimates? (Zacks)
09:55AM	How Much Upside is Left in Amicus Therapeutics (FOLD)? Wall Street Analysts Think 43.44% (Zacks)
09:55AM	Amicus Therapeutics (FOLD) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
06:41AM	Amicus Therapeutics (FOLD) Stock Jumps 14.0%: Will It Continue to Soar? (Zacks)
Oct-17-24 11:07AM	Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug (Benzinga) +14.00%
07:00AM	Amicus Therapeutics Announces Settlement of Galafold (migalastat) Patent Litigation with Teva (GlobeNewswire)
Oct-09-24 05:35PM	Amicus Therapeutics Inc (FOLD) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Oct-07-24 05:02PM	JPMorgan Chase & Co's Strategic Reduction in Amicus Therapeutics Inc (GuruFocus.com)
Oct-04-24 07:00AM	Amicus Therapeutics Announces Participation at the World Muscle Society Annual Congress 2024 (GlobeNewswire)
Sep-24-24 11:50PM	Is Amicus Therapeutics, Inc. (FOLD) the Best Guru Stock To Buy Now? (Insider Monkey)
Sep-03-24 07:46AM	UPDATE -- Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024 (GlobeNewswire)
07:05AM	Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024 (GlobeNewswire)
07:00AM	Amicus Therapeutics Announces Participation at the SSIEM 2024 Annual Symposium (GlobeNewswire)
Aug-30-24 07:00AM	Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024 (GlobeNewswire)
Aug-21-24 11:24AM	Amicus (FOLD) Banks on Galafold, High Dependence a Concern (Zacks)
Aug-09-24 10:31AM	Amicus (FOLD) Up as Q2 Earnings & Sales Top, '24 View Updated (Zacks)
Aug-08-24 09:00PM	Amicus Therapeutics (FOLD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) +13.20%
08:25AM	Amicus Therapeutics (FOLD) Q2 Earnings and Revenues Top Estimates (Zacks)
07:22AM	Amicus Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Amicus Therapeutics Announces Second Quarter 2024 Financial Results and Corporate Updates (GlobeNewswire)
Jul-30-24 07:00AM	Amicus Therapeutics to Announce Second Quarter 2024 Financial Results on August 8, 2024 (GlobeNewswire)
Jun-26-24 09:47AM	Do Options Traders Know Something About Amicus (FOLD) Stock We Don't? (Zacks)
Jun-05-24 07:00AM	Amicus Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
Jun-04-24 07:00AM	Amicus Therapeutics Receives Prix Galien U.K. Award for Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) as Best Pharmaceutical Product (GlobeNewswire)
May-24-24 08:30AM	Do Options Traders Know Something About Amicus (FOLD) Stock We Don't? (Zacks)
May-14-24 07:15AM	Guggenheim Upgrades Amicus Therapeutics to Buy From Neutral With $13 Price Target (MT Newswires)
May-10-24 04:03PM	Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q1 2024 Earnings Call Transcript (Insider Monkey)
01:10PM	Amicus Therapeutics Inc (FOLD) Q1 2024 Earnings: Surpasses Revenue Estimates and Projects ... (GuruFocus.com)
11:33AM	UBS Trims Price Target on Amicus Therapeutics to $19 From $20, Keeps Buy Rating (MT Newswires)
10:46AM	Amicus (FOLD) Q1 Earnings Top, Sales Lag, '24 Outlook Updated (Zacks)
May-09-24 10:30PM	Amicus Therapeutics (FOLD) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks) -6.51%
11:56AM	FOLD Stock Earnings: Amicus Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:26AM	Amicus Therapeutics' Q1 Net Loss Narrows, Net Product Sales Rise (MT Newswires)
08:25AM	Amicus Therapeutics (FOLD) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:21AM	Amicus Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates (GlobeNewswire)
May-08-24 07:00AM	Amicus Therapeutics to Present at the Bank of America 2024 Health Care Conference (GlobeNewswire)
May-01-24 10:01AM	Will Amicus Therapeutics (FOLD) Report Negative Q1 Earnings? What You Should Know (Zacks)

Amicus Therapeutics, Inc. is a biotechnology company, which focuses on discovering, developing, and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Campbell Bradley L	President and CEO	Feb 19 '25	Option Exercise	9.03	400	3,612	1,151,057	Feb 21 07:27 PM
Campbell Bradley L	President and CEO	Feb 19 '25	Sale	10.00	400	4,000	1,150,657	Feb 21 07:27 PM
BRADLEY CAMPBELL	Director	Feb 19 '25	Proposed Sale	9.85	400	3,940		Feb 19 04:36 PM
Campbell Bradley L	President and CEO	Dec 02 '24	Option Exercise	8.61	7,500	64,575	894,154	Dec 03 06:12 PM
Campbell Bradley L	President and CEO	Dec 02 '24	Sale	10.02	7,500	75,124	886,654	Dec 03 06:12 PM
BRADLEY CAMPBELL	Director	Dec 02 '24	Proposed Sale	9.98	7,500	74,850		Dec 02 04:43 PM
Campbell Bradley L	President and CEO	Nov 06 '24	Option Exercise	12.28	7,901	97,024	894,555	Nov 07 05:49 PM
Campbell Bradley L	President and CEO	Nov 06 '24	Sale	12.50	7,901	98,800	886,654	Nov 07 05:49 PM
BRADLEY CAMPBELL	Director	Nov 06 '24	Proposed Sale	11.74	7,901	92,758		Nov 06 05:03 PM
Campbell Bradley L	President and CEO	Nov 01 '24	Option Exercise	8.61	7,500	64,575	894,154	Nov 04 06:23 PM
Campbell Bradley L	President and CEO	Nov 01 '24	Sale	11.46	7,500	85,960	886,654	Nov 04 06:23 PM
BRADLEY CAMPBELL	Director	Nov 01 '24	Proposed Sale	11.42	7,500	85,650		Nov 01 04:49 PM
Campbell Bradley L	President and CEO	Oct 01 '24	Option Exercise	8.61	7,500	64,575	894,154	Oct 04 04:05 PM
Campbell Bradley L	President and CEO	Oct 01 '24	Sale	10.60	7,500	79,492	886,654	Oct 04 04:05 PM
BRADLEY CAMPBELL	Director	Oct 01 '24	Proposed Sale	10.68	7,500	80,100		Oct 01 04:35 PM
Campbell Bradley L	President and CEO	Sep 03 '24	Option Exercise	8.61	7,500	64,575	894,154	Sep 05 05:01 PM
Campbell Bradley L	President and CEO	Sep 03 '24	Sale	11.71	7,500	87,798	886,654	Sep 05 05:01 PM
BRADLEY CAMPBELL	Director	Sep 03 '24	Proposed Sale	11.61	7,500	87,075		Sep 03 04:19 PM
Campbell Bradley L	President and CEO	Aug 01 '24	Option Exercise	8.61	7,500	64,575	894,154	Aug 05 08:10 PM
Campbell Bradley L	President and CEO	Aug 01 '24	Sale	10.34	7,500	77,518	886,654	Aug 05 08:10 PM
BRADLEY CAMPBELL	Director	Aug 01 '24	Proposed Sale	10.31	7,500	77,325		Aug 01 04:25 PM
Campbell Bradley L	President and CEO	Jul 05 '24	Option Exercise	8.61	6,100	52,521	892,754	Jul 09 05:01 PM
Campbell Bradley L	President and CEO	Jul 05 '24	Sale	10.00	6,100	61,029	886,654	Jul 09 05:01 PM
Campbell Bradley L	President and CEO	Jul 01 '24	Option Exercise	8.61	1,400	12,054	888,054	Jul 03 04:22 PM
Campbell Bradley L	President and CEO	Jul 01 '24	Sale	10.00	1,400	14,003	886,654	Jul 03 04:22 PM
Campbell Bradley L	President and CEO	Jun 03 '24	Option Exercise	8.61	7,500	64,575	894,154	Jun 05 04:35 PM
Campbell Bradley L	President and CEO	Jun 03 '24	Sale	10.00	7,500	75,000	886,654	Jun 05 04:35 PM

Dollar change +14.38
Percentage change 3.38	%

VRTX Vertex Pharmaceuticals, Inc daily Stock Chart

Peers: BIIB GILD AMGN REGN MRNA INCY ALNY NBIX EXEL

| Held by: VTI VOO QQQ VUG SPY IVV XLV IBB VHT QQQM

Index	NDX, S&P 500	P/E	-	EPS (ttm)	-3.92	Insider Own	0.29%	Shs Outstand	256.97M	Perf Week	-12.16%
Market Cap	112.83B	Forward P/E	21.03	EPS next Y	20.89	Insider Trans	-7.20%	Shs Float	256.04M	Perf Month	-7.60%
Income	-988.90M	PEG	-	EPS next Q	4.30	Inst Own	93.56%	Short Float	1.48%	Perf Quarter	-6.51%
Sales	11.04B	P/S	10.22	EPS this Y	4182.49%	Inst Trans	-4.77%	Short Ratio	2.27	Perf Half Y	-10.99%
Book/sh	64.20	P/B	6.84	EPS next Y	16.16%	ROA	-4.23%	Short Interest	3.78M	Perf Year	4.91%
Cash/sh	24.19	P/C	18.16	EPS next 5Y	-	ROE	-5.64%	52W Range	377.85 - 519.88	Perf YTD	9.11%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-5.45%	52W High	-15.49%	Beta	0.48
Dividend TTM	-	Quick Ratio	2.29	Sales past 5Y	22.39%	Gross Margin	85.96%	52W Low	16.28%	ATR (14)	16.81
Dividend Ex-Date	-	Current Ratio	2.65	EPS Y/Y TTM	-124.45%	Oper. Margin	-2.99%	RSI (14)	34.57	Volatility	4.34% 2.94%
Employees	6100	Debt/Eq	0.10	Sales Y/Y TTM	8.55%	Profit Margin	-8.95%	Recom	2.06	Target Price	510.04
Option/Short	Yes / Yes	LT Debt/Eq	0.10	EPS Q/Q	-40.86%	Payout	-	Rel Volume	1.26	Prev Close	424.99
Sales Surprise	-3.20%	EPS Surprise	-4.37%	Sales Q/Q	2.19%	Earnings	May 05 AMC	Avg Volume	1.66M	Price	439.37
SMA20	-8.53%	SMA50	-9.97%	SMA200	-6.55%	Trades		Volume	2,094,864	Change	3.38%

Date	Action	Analyst	Rating Change	Price Target Change
May-07-25	Downgrade	Wolfe Research	Outperform → Peer Perform
May-06-25	Downgrade	Leerink Partners	Outperform → Market Perform	$503
Apr-22-25	Resumed	Cantor Fitzgerald	Overweight	$535
Feb-12-25	Upgrade	Canaccord Genuity	Sell → Hold	$408 → $424
Feb-11-25	Upgrade	Canaccord Genuity	Sell → Hold
Jan-30-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$460
Dec-20-24	Reiterated	H.C. Wainwright	Buy	$600 → $535
Dec-19-24	Downgrade	Oppenheimer	Outperform → Perform
Dec-09-24	Upgrade	Jefferies	Hold → Buy	$500 → $550
Nov-14-24	Initiated	Citigroup	Buy	$575
Oct-16-24	Initiated	Scotiabank	Sector Perform
Oct-10-24	Resumed	Raymond James	Mkt Perform
Aug-05-24	Downgrade	Barclays	Overweight → Equal Weight	$472 → $509
Jun-27-24	Initiated	Redburn Atlantic	Buy	$545
Apr-11-24	Upgrade	Evercore ISI	In-line → Outperform	$438
Feb-15-24	Initiated	Wolfe Research	Outperform	$515
Feb-06-24	Downgrade	Evercore ISI	Outperform → In-line	$436 → $438
Feb-02-24	Downgrade	Bernstein	Outperform → Mkt Perform
Jan-31-24	Downgrade	Robert W. Baird	Neutral → Underperform	$325
Jan-31-24	Downgrade	Maxim Group	Buy → Hold

Show Previous Ratings

Today 07:08AM	Prediction: These 2 Stocks Will Outperform the Market in the Next Five Years (Motley Fool)
May-11-25 04:55PM	Is Vertex Pharmaceuticals (VRTX) Among the Best Stocks to Buy According to Jim Simons' Renaissance Technologies? (Insider Monkey)
May-10-25 04:12AM	My Favorite Tariff Safe-Haven Stock to Buy on the Dip (Motley Fool)
May-09-25 10:03AM	Vertex Pharmaceuticals Incorporated (VRTX) Surged On a Recovery in Investor Sentiment (Insider Monkey)
09:00AM	Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know (Zacks)
06:30AM	Loading…
06:30AM	4 No-Brainer Stocks to Buy Right Now (Motley Fool)
May-08-25 08:03AM	Viatris new form of old pain drug scores in large trials (BioPharma Dive)
May-07-25 04:03PM	Crispr Therapeutics Q1 Earnings Analysis: Ignore The Gloom, Stay The Course (Seeking Alpha)
03:30PM	Vertex Pharma extends selloff as Wolfe downgrades after Q1 miss (Seeking Alpha)
12:16PM	S&P 500's five most overbought and oversold stocks (Seeking Alpha)
12:06PM	SA analyst upgrades: TSLA, MSFT, AMD, PLTR, VRTX, ONON, CB (Seeking Alpha)
07:40AM	CRISPR Therapeutics Q1 Earnings and Sales Miss Estimates, Stock Tanks (Zacks)
07:26AM	VRTX Stock Down as Q1 Sales of New Drugs Miss Expectations (Zacks)
04:49AM	Why Vertex Pharmaceuticals Stock Is a Screaming Buy on the Dip (Motley Fool)
12:31AM	1 S&P 500 Stock with Impressive Fundamentals and 2 to Ignore (StockStory)
07:52PM	Loading…
May-06-25 07:52PM	Analyst Report: Vertex Pharmaceuticals Incorporated (Morningstar Research) -10.03%
05:09PM	Stocks to Watch Recap: Palantir, Ford, Mattel, DoorDash (The Wall Street Journal)
04:49PM	S&P 500 Gains & Losses Today: Stocks Fall for Second Day as Palantir, Pharmaceuticals Drop (Investopedia)
04:39PM	Vertex Pharmaceuticals Topples 10% On A Series Of First-Quarter Setbacks (Investor's Business Daily)
04:28PM	Why Did Vertex Pharmaceuticals Stock Fall On Tuesday? (Benzinga)
04:25PM	Stock Market Today: Dow Jones, S&P 500 Fall Again; Gold Stocks Rally While Palantir Tumbles (Live Coverage) (Investor's Business Daily)
03:18PM	Jim Cramer on Vertex (VRTX): "Vertex's Painkiller Could Be Revolutionary" (Insider Monkey)
02:41PM	Stocks to Watch Tuesday: Palantir, Ford, Mattel, DoorDash (The Wall Street Journal)
02:08PM	Uber-Pony AI partnership, EVgo boost, Vertex earnings miss (Yahoo Finance Video)
12:31PM	Vertex Pharmaceuticals Stock Is Tumbling After Earnings. Heres Why. (Barrons.com)
11:59AM	VRTX's Q1 Earnings Lag Estimates, 2025 Revenue View Tightened (Zacks)
11:58AM	Top Stock Movers Now: Vertex, DoorDash, Constellation Energy, and More (Investopedia)
10:48AM	Vertex Pharmaceuticals Stock Sinks as Costs Soar (Investopedia)
10:36AM	Why Vertex Pharmaceuticals Stock Is Sinking Today (Motley Fool)
09:11AM	Rising Costs Weigh on Vertex Q1 Earnings (Motley Fool)
07:29AM	Loading…
07:29AM	Q1 2025 Vertex Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
03:06AM	Vertex Pharmaceuticals Inc (VRTX) Q1 2025 Earnings Call Highlights: Revenue Growth Amid Challenges (GuruFocus.com)
May-05-25 08:01PM	Vertex Pharmaceuticals Incorporated (VRTX) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:15PM	Vertex Pharmaceuticals (VRTX) Misses Q1 Earnings and Revenue Estimates (Zacks)
04:17PM	Vertex misses quarterly results on weaker-than-expected sales for cystic fibrosis drug (Reuters)
04:09PM	Vertex: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Vertex Reports First Quarter 2025 Financial Results (Business Wire)
07:00AM	Stock Market Selloff: 4 No-Brainer Stocks to Buy Right Now (Motley Fool)
06:45AM	3 No-Brainer Stocks to Buy in May (Motley Fool)
04:44AM	CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts (Seeking Alpha)
May-04-25 07:42AM	Wall Street Week Ahead (Seeking Alpha)
06:00AM	What To Expect in the Markets This Week (Investopedia)
04:42AM	5 Growth Stocks to Buy in May and Go Away (Motley Fool)
May-03-25 11:00AM	Ford, Disney, And AMD To Report Results Next Week (Seeking Alpha)
May-02-25 01:20PM	Viatris Q1 Earnings Release: What's in Store for the Stock? (Zacks)
May-01-25 09:35AM	ClearBridge Growth Portfolios Q1 2025 Commentary (Seeking Alpha)
09:30AM	ClearBridge Growth ESG Portfolios Q1 2025 Commentary (Seeking Alpha)
09:15AM	ClearBridge All Cap Growth Portfolios Q1 2025 Commentary (Seeking Alpha)
Apr-30-25 09:35PM	ClearBridge Growth Fund Q1 2025 Commentary (Seeking Alpha)
05:50PM	Vertex Pharmaceuticals (VRTX) Outperforms Broader Market: What You Need to Know (Zacks)
10:15AM	The Davenport Core Leaders Fund Q1 2025 Commentary (Seeking Alpha)
09:15AM	What Analyst Projections for Key Metrics Reveal About Vertex (VRTX) Q1 Earnings (Zacks)
Apr-29-25 11:45AM	Baron Health Care Fund Q1 2025 Top Net Purchases And Sales (Seeking Alpha)
11:30AM	Baron Health Care Fund Q1 2025 Top Contributors And Detractors (Seeking Alpha)
10:01AM	Analysts Estimate Entrada Therapeutics, Inc. (TRDA) to Report a Decline in Earnings: What to Look Out for (Zacks)
07:51AM	Vertex Gears Up to Report Q1 Earnings: Is a Beat in the Cards? (Zacks)
06:20AM	Should You Invest in the VanEck Biotech ETF (BBH)? (Zacks)
Apr-28-25 10:00AM	Vertex Pharmaceuticals (VRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
04:48AM	My 5 Top Stocks to Buy Right Now in This Highly Volatile Market (Motley Fool)
Apr-27-25 02:22PM	Baron Health Care Fund Q1 2025 Shareholder Letter (Seeking Alpha)
07:00AM	Wall Streets New Tariff Safe Haven: High-Tax Biotech Stocks (The Wall Street Journal)
Apr-25-25 01:29PM	Exelixis' Q1 Earnings: Will Cabometyx Maintain Momentum? (Zacks)
11:59AM	CRISPR Therapeutics to Report Q1 Earnings: What's in the Cards? (Zacks)
Apr-24-25 05:50PM	Vertex Pharmaceuticals (VRTX) Advances But Underperforms Market: Key Facts (Zacks)
01:49PM	Top 20 biopharmas market cap rises 6% in Q1 2025 amid tariff headwinds (Pharmaceutical Technology)
Apr-23-25 09:00AM	Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Apr-22-25 05:37PM	Why Vertex Pharmaceuticals Was Such a Healthy Stock on Tuesday (Motley Fool)
02:29PM	Regeneron to Report Q1 Earnings: What's in Store for the Stock? (Zacks)
09:53AM	3 Relatively Safe Healthcare Growth Stocks You Can Buy and Hold (Motley Fool)
08:50AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
04:47AM	Fed Chairman Jerome Powell Warns Trump's Tariffs Could Cause Stagflation: 3 Stocks to Buy and Hold if He's Right (Motley Fool)
Apr-21-25 01:36PM	Novartis to Report Q1 Earnings: Will Key Drugs Maintain Momentum? (Zacks)
07:30AM	uniQure: Huntington's Gene Therapy Advances, But Commercial Hurdles Keep This A Hold (Seeking Alpha)
Apr-18-25 06:30AM	Don't Try to Time the Market: These 2 Stocks Are Buys Regardless of What Happens Next (Motley Fool)
Apr-17-25 06:20AM	Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now? (Zacks)
Apr-16-25 06:20AM	Should First Trust NASDAQ-100 Ex-Technology Sector ETF (QQXT) Be on Your Investing Radar? (Zacks)
Apr-15-25 04:45AM	Stock Market Whiplash: 3 Growth Stocks That Are No-Brainer Buys on the Bounce (Motley Fool)
Apr-14-25 10:51PM	Aristotle Atlantic's Core Equity Q1 2025 Commentary (Seeking Alpha)
06:20AM	Should First Trust NASDAQ-100 Equal Weighted ETF (QQEW) Be on Your Investing Radar? (Zacks)
Apr-12-25 04:48AM	Nasdaq Market Whiplash: 3 Stocks to Buy Hand Over Fist and Hold for Decades (Motley Fool)
Apr-11-25 05:30AM	Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis (Business Wire)
03:45AM	Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals? (Motley Fool)
Apr-10-25 05:50PM	Vertex Pharmaceuticals (VRTX) Stock Moves -1.41%: What You Should Know (Zacks)
08:55AM	Vertex Pharmaceuticals (VRTX) Surged on Increased Demand for its Cystic Fibrosis (CF) Franchise (Insider Monkey)
08:55AM	GreensKeeper Q1 2025 Portfolio Update (Seeking Alpha)
08:19AM	ClearBridge Growth Strategy Q1 2025 Commentary (Seeking Alpha)
03:52AM	We're About to Find Out the Answer to Warren Buffett's Pointed Question About Trump's Tariffs. Here Are 3 Stocks to Buy Depending on What That Answer Is. (Motley Fool)
Apr-09-25 10:00AM	5 Top Growth Stocks to Buy in the Stock Market Sell-Off (Motley Fool)
09:00AM	Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know (Zacks)
07:10AM	GreensKeeper Value Fund Q1 2025 Letter (Seeking Alpha)
Apr-08-25 02:24PM	Jim Cramer Calls Vertex Pharmaceuticals Incorporated (VRTX) "Terrific" With "Revolutionary Pain Drug" (Insider Monkey)
02:09PM	Is Vertex Pharmaceuticals Incorporated (VRTX) the Best Long Term Growth Stock to Buy According to Billionaires? (Insider Monkey)
09:45AM	Is Vertex Pharmaceuticals Stock a Buy? (Motley Fool)
06:55AM	VRTX Secures Nod for Expanded Use of CF Drug Kaftrio in Europe (Zacks)
Apr-07-25 04:05PM	Vertex to Announce First Quarter 2025 Financial Results on May 5th (Business Wire)
12:00PM	European Commission Approves Expanded Label for KAFTRIO in Combination With Ivacaftor for People With Cystic Fibrosis (Business Wire)
06:20AM	Should You Invest in the iShares Biotechnology ETF (IBB)? (Zacks)
05:24AM	2 Stocks to Buy if You're Worried About a Recession (Motley Fool)
Apr-06-25 08:38AM	Krystal Biotech: Some Uncertainty, Some Value (Seeking Alpha)
05:45AM	Worried About Trump's New Tariffs? These 3 U.S. Companies Are Set to Weather the Storm (Motley Fool)

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bhatia Sangeeta N.	Director	May 02 '25	Sale	505.86	400	202,344	4,831	May 05 04:14 PM
Bhatia Sangeeta N.	Director	May 02 '25	Proposed Sale	505.86	400	202,344		May 02 09:47 AM
ALTSHULER DAVID	EVP, Chief Scientific Officer	Mar 13 '25	Sale	510.00	3,231	1,647,810	23,281	Mar 17 04:09 PM
ALTSHULER DAVID	Officer	Mar 13 '25	Proposed Sale	510.00	3,231	1,647,810		Mar 13 11:10 AM
WAGNER CHARLES F JR	EVP & Chief Financial Officer	Mar 10 '25	Sale	500.00	3,298	1,649,000	51,671	Mar 12 04:11 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Mar 10 '25	Sale	499.99	3,242	1,620,968	51,239	Mar 12 04:10 PM
ALTSHULER DAVID	EVP, Chief Scientific Officer	Mar 10 '25	Sale	500.00	3,231	1,615,500	26,512	Mar 12 04:08 PM
Tatsis Ourania	Officer	Mar 10 '25	Proposed Sale	499.99	3,242	1,620,968		Mar 10 01:58 PM
WAGNER CHARLES F JR	Officer	Mar 10 '25	Proposed Sale	500.00	3,298	1,649,000		Mar 10 01:02 PM
ALTSHULER DAVID	Officer	Mar 10 '25	Proposed Sale	500.00	3,231	1,615,500		Mar 10 12:42 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Mar 04 '25	Sale	485.49	4,058	1,970,118	54,481	Mar 06 04:08 PM
ALTSHULER DAVID	EVP, Chief Scientific Officer	Mar 03 '25	Sale	490.00	3,231	1,583,190	29,743	Mar 05 04:08 PM
Tatsis Ourania	Officer	Mar 04 '25	Proposed Sale	485.49	4,058	1,970,118		Mar 04 01:39 PM
ALTSHULER DAVID	Officer	Mar 03 '25	Proposed Sale	490.00	3,231	1,583,190		Mar 03 04:17 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Feb 27 '25	Sale	475.34	530	251,930	58,539	Feb 28 04:48 PM
Atkinson Edward Morrow III	EVP, Chief Technical Ops. Off.	Feb 27 '25	Sale	475.34	2,650	1,259,651	19,352	Feb 28 04:36 PM
ALTSHULER DAVID	EVP, Chief Scientific Officer	Feb 27 '25	Sale	480.00	1,272	610,560	32,974	Feb 28 04:23 PM
ALTSHULER DAVID	Officer	Feb 27 '25	Proposed Sale	480.00	1,272	610,560		Feb 27 11:20 AM
Atkinson Edward Morrow III	Officer	Feb 27 '25	Proposed Sale	475.34	2,650	1,259,651		Feb 27 10:18 AM
Tatsis Ourania	Officer	Feb 27 '25	Proposed Sale	475.34	530	251,930		Feb 27 10:14 AM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Feb 25 '25	Sale	480.95	354	170,256	64,031	Feb 26 04:15 PM
Atkinson Edward Morrow III	EVP, Chief Technical Ops. Off.	Feb 25 '25	Sale	480.95	1,767	849,839	24,484	Feb 26 04:09 PM
Ambrose Kristen	SVP & Chief Accounting Officer	Feb 25 '25	Sale	480.95	884	425,160	9,086	Feb 26 04:06 PM
ALTSHULER DAVID	EVP, Chief Scientific Officer	Feb 25 '25	Sale	480.95	848	407,846	40,200	Feb 26 04:04 PM
Tatsis Ourania	Officer	Feb 25 '25	Proposed Sale	480.95	354	170,256		Feb 25 11:38 AM
ALTSHULER DAVID	Officer	Feb 25 '25	Proposed Sale	480.95	848	407,846		Feb 25 11:13 AM
Atkinson Edward Morrow III	Officer	Feb 25 '25	Proposed Sale	480.95	1,767	849,839		Feb 25 10:59 AM
ALTSHULER DAVID	EVP, Chief Scientific Officer	Feb 20 '25	Sale	480.00	1,111	533,280	45,019	Feb 24 04:07 PM
ALTSHULER DAVID	Officer	Feb 20 '25	Proposed Sale	480.00	1,111	533,280		Feb 20 03:45 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Feb 18 '25	Sale	455.06	244	111,035	67,695	Feb 19 04:36 PM
Biller Jonathan	EVP and Chief Legal Officer	Feb 18 '25	Sale	455.06	1,657	754,034	17,606	Feb 19 04:28 PM
Ambrose Kristen	SVP & Chief Accounting Officer	Feb 18 '25	Sale	455.06	671	305,345	10,798	Feb 19 04:21 PM
Tatsis Ourania	Officer	Feb 18 '25	Proposed Sale	455.06	244	111,035		Feb 18 11:34 AM
Biller Jonathan	Officer	Feb 18 '25	Proposed Sale	455.06	1,657	754,034		Feb 18 11:29 AM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Feb 11 '25	Sale	459.83	310	142,547	64,021	Feb 12 04:50 PM
Biller Jonathan	EVP and Chief Legal Officer	Feb 11 '25	Sale	459.87	3,433	1,578,734	16,330	Feb 12 04:36 PM
Atkinson Edward Morrow III	EVP, Chief Technical Ops. Off.	Feb 11 '25	Sale	459.83	1,747	803,323	23,225	Feb 12 04:29 PM
Ambrose Kristen	SVP & Chief Accounting Officer	Feb 11 '25	Sale	459.83	1,376	632,726	9,953	Feb 12 04:24 PM
Biller Jonathan	Officer	Feb 11 '25	Proposed Sale	459.87	3,433	1,578,744		Feb 11 11:57 AM
Tatsis Ourania	Officer	Feb 11 '25	Proposed Sale	459.83	310	142,547		Feb 11 11:05 AM
Atkinson Edward Morrow III	Officer	Feb 11 '25	Proposed Sale	459.83	1,747	803,323		Feb 11 09:49 AM
ALTSHULER DAVID	EVP, Chief Scientific Officer	Nov 15 '24	Sale	478.56	15	7,178	25,813	Nov 19 04:08 PM
ALTSHULER DAVID	Officer	Nov 15 '24	Proposed Sale	478.56	15	7,178		Nov 15 10:31 AM
WAGNER CHARLES F JR	EVP & Chief Financial Officer	Nov 11 '24	Sale	518.27	3,000	1,554,810	44,137	Nov 13 04:15 PM
Kewalramani Reshma	CEO & President	Nov 08 '24	Sale	515.00	15,198	7,826,970	75,772	Nov 12 04:08 PM
Kewalramani Reshma	Officer	Nov 08 '24	Proposed Sale	515.00	15,198	7,826,970		Nov 08 02:58 PM
Biller Jonathan	EVP and Chief Legal Officer	Oct 02 '24	Sale	461.66	999	461,198	16,651	Oct 03 04:12 PM
Biller Jonathan	Officer	Oct 02 '24	Proposed Sale	461.66	999	461,198		Oct 02 10:04 AM
LEIDEN JEFFREY M	Executive Chairman	Aug 30 '24	Sale	499.00	3,784	1,888,216	9,994	Sep 04 04:13 PM
Bhatia Sangeeta N.	Director	Aug 30 '24	Option Exercise	152.74	646	98,670	5,081	Sep 04 04:12 PM
Bhatia Sangeeta N.	Director	Aug 30 '24	Sale	500.00	646	323,000	4,435	Sep 04 04:12 PM
Bhatia Sangeeta N.	Director	Aug 30 '24	Proposed Sale	500.00	646	323,000		Aug 30 04:47 PM
JEFFREY LEIDEN	Director	Aug 30 '24	Proposed Sale	493.35	3,784	1,866,836		Aug 30 04:23 PM
Bhatia Sangeeta N.	Director	Aug 08 '24	Option Exercise	152.74	1,292	197,340	5,727	Aug 12 04:08 PM
Bhatia Sangeeta N.	Director	Aug 08 '24	Sale	466.29	1,292	602,447	4,435	Aug 12 04:08 PM
Bozic Carmen	EVP and CMO	Aug 07 '24	Sale	476.75	2,280	1,086,990	23,259	Aug 08 04:06 PM
Bhatia Sangeeta N.	Director	Aug 08 '24	Proposed Sale	466.29	1,292	602,447		Aug 08 11:47 AM
Bozic Carmen	Officer	Aug 07 '24	Proposed Sale	476.75	2,280	1,086,990		Aug 07 09:52 AM
SACHS BRUCE I	Director	Aug 01 '24	Option Exercise	125.71	5,295	665,634	45,295	Aug 02 04:10 PM
SACHS BRUCE I	Director	Aug 01 '24	Sale	508.00	5,295	2,689,860	40,000	Aug 02 04:10 PM
Kewalramani Reshma	CEO & President	Jul 30 '24	Sale	505.00	15,202	7,677,010	90,970	Aug 01 04:17 PM
SACHS BRUCE I	Director	Aug 01 '24	Proposed Sale	508.00	5,295	2,689,860		Aug 01 03:34 PM
Kewalramani Reshma	Officer	Jul 30 '24	Proposed Sale	505.00	15,202	7,677,010		Jul 30 03:25 PM
Bozic Carmen	EVP and CMO	Jul 24 '24	Sale	488.46	2,280	1,113,689	25,539	Jul 25 04:06 PM
Kewalramani Reshma	CEO & President	Jul 22 '24	Sale	497.00	15,202	7,555,394	106,172	Jul 24 04:05 PM
Bozic Carmen	EVP and CMO	Jul 10 '24	Sale	487.34	2,280	1,111,135	27,819	Jul 12 04:07 PM
Bozic Carmen	EVP and CMO	Jun 26 '24	Sale	471.72	2,280	1,075,522	30,099	Jun 28 04:04 PM
Bozic Carmen	EVP and CMO	Jun 12 '24	Sale	478.00	2,280	1,089,840	32,379	Jun 13 04:11 PM
Atkinson Edward Morrow III	EVP, Chief Technical Ops. Off.	Jun 12 '24	Sale	478.00	7,288	3,483,664	15,972	Jun 13 04:09 PM
WAGNER CHARLES F JR	EVP & Chief Financial Officer	Jun 03 '24	Sale	460.00	3,250	1,495,000	47,137	Jun 05 04:11 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Jun 03 '24	Sale	460.00	2,175	1,000,500	49,098	Jun 05 04:08 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	May 30 '24	Sale	439.11	2,350	1,031,908	53,523	Jun 03 04:09 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	May 31 '24	Sale	445.00	2,250	1,001,250	51,273	Jun 03 04:09 PM
Bozic Carmen	EVP and CMO	May 29 '24	Sale	445.56	2,280	1,015,877	34,659	May 31 04:19 PM
WAGNER CHARLES F JR	EVP & Chief Financial Officer	May 28 '24	Sale	454.79	3,250	1,478,068	50,387	May 30 04:07 PM
Kewalramani Reshma	CEO & President	May 24 '24	Option Exercise	187.53	1,565	293,484	122,939	May 29 04:08 PM
Kewalramani Reshma	CEO & President	May 24 '24	Sale	457.00	1,565	715,205	121,374	May 29 04:08 PM
SACHS BRUCE I	Director	May 22 '24	Option Exercise	93.51	7,073	661,396	47,073	May 24 04:13 PM
SACHS BRUCE I	Director	May 22 '24	Sale	448.00	7,073	3,168,704	40,000	May 24 04:13 PM
Kewalramani Reshma	CEO & President	May 20 '24	Sale	447.00	15,202	6,795,294	121,374	May 22 04:21 PM
Sachdev Amit	EVP Chief Patient & Ext Af Off	May 15 '24	Sale	430.93	32	13,790	55,325	May 17 04:27 PM
Arbuckle Stuart A	EVP, COO	May 15 '24	Sale	430.93	69	29,734	49,691	May 17 04:24 PM
ALTSHULER DAVID	EVP, Chief Scientific Officer	May 15 '24	Sale	430.93	54	23,270	25,813	May 17 04:22 PM

FOLD

Amicus Therapeutics Inc

VRTX

Vertex Pharmaceuticals, Inc

Upgrade your FINVIZ experience